Lupus & antiphospholipid syndrome
Early haematologic response to anifrolumab in SLE: results from the European multicentre EFFORT-SLE study
Authors' conclusion
ANI was associated with early haematologic improvement, with one-third of patients achieving complete normalization under a stringent definition of remission.
Study context
- Population
- Adults with SLE with ≥1 disease-related haematologic abnormality at anifrolumab initiation, seven European countries91.5% female
- Participants
- 47 adults
- Outcome
- Complete haematologic response (CHR): normalization of all baseline abnormalities
Methodological detailsmulticentre, European, Data at baseline and at 3, 6, 12, 18 and 24 months, anifrolumab (ANI) initiated for haematologic involvement in 21/47 (44.7%); for other SLE manifestations in 26/47 (55.3%)
- Multicentre
- European
- Data at baseline and at 3, 6, 12, 18 and 24 months
- ANI initiated for haematologic involvement in 21/47 (44.7%); for other SLE manifestations in 26/47 (55.3%)
Main finding
As reported in the abstract
CHR
Complete haematologic response (CHR) at 3 months
8 of 43
18.6%
CHR cumulatively within 6 months
14 of 46
30.4%
CHR overall
17/47, 36.2%
Observational data: associations, not effects.
Further findings
Partial haematologic response (PHR): normalization of ≥1 affected lineage
- PHR at 3 months
- 17/43 (39.5%)
- PHR at 6 months
- 11/37 (29.7%)
Blood counts · month 3
- Haemoglobin, leucocyte and lymphocyte counts significantly improved
- Platelet counts: non-significant increase
Predictors of no CHR
- Higher baseline CRP, ESR and SLE-DAS associated with lack of CHR
Safety
Discontinuation of ANI
- Discontinued ANI
- 12 (25.5%)
Adverse events without discontinuation
- AEs without discontinuation
- 17 (36.2%)
Original publication
Early haematologic response to anifrolumab in SLE: results from the European multicentre EFFORT-SLE study. Rheumatology (Oxford). Published 11 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →